Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD

Table 3

Results of Anti-VEGF therapy in eyes with neovascular age-related macular degeneration.

	0 ()	Pack-years of smoking		Duration of smoking (yrs)		Time since cessation of smoking (yrs)
		<40 ()	40≤ ()	<40 ()	40≤ ()	<20 ()	20≤ ()
Outcome, mean (SD)
VA (logMAR)	0.29 (0.36)	0.24 (0.32)	0.14 (0.23)	0.14 (0.23)	0.25 (0.34)	0.24 (0.31)	0.12 (0.26)
Central retinal thickness (µm)	241.7 (85.1)	216.8 (50.7)	241.8 (75.7)	223.8 (52.5)	226.3 (67.1)	240.6 (75.2)	219.8 (42.0)
Subfoveal choroidal thickness (µm)	201.3 (88.1)	241.1 (135.4)	189.3 (111.8)	269.4 (150.3)	187.4 (97.8)	173.9 (96.0)	249.8 (147.1)
Change, mean (SD)
VA (logMAR)	−0.08 (0.39)	−0.03 (0.33)	−0.15 (0.28)	−0.07 (0.17)	−0.08 (0.40)	−0.08 (0.32)	−0.06 (0.19)
Central retinal thickness (µm)	100.4 (100.2)	87.4 (72.0)	44.8 (105.1)	63.4 (58.2)	81.1 (103.0)	66.31 (102.2)	62.3 (66.1)
Subfoveal choroidal thickness (µm)	38.0 (38.8)	29.1 (39.4)	15.3 (56.9)	39.9 (38.9)	24.3 (51.9)	30.31 (46.8)	40.8 (38.6)
No. of injections (no./yrs)	5.3 (2.6)	5.2 (2.5)	7.3 (2.5)	5.2 (2.7)	6.5 (2.6)	6.9 (2.2)	5.5 (2.7)
IVR (no./patients)	6.1 (0.2)	3.8 (0.3)	7.6 (0.6)	2.9 (0.3)	6.8 (0.4)	6.8 (0.5)	2.7 (0.4)
IVA (no./patients)	14.2 (0.4)	12.0 (0.4)	19.9 (0.9)	12.4 (0.6)	16.5 (0.5)	17.6 (0.6)	14.6 (0.9)

One-way ANOVA followed by Tukey’s post hoc test.